The Role of Gemcitabine in Combined Modality Therapy

Jerome Landry; William Blackstock; Robert M. MacRae; Gary Yang; Hak Choy; Gary Y. Yang

doi:10.1007/978-1-59259-325-5_6

The Role of Gemcitabine in Combined Modality Therapy

Jerome Landry, William Blackstock, Robert M. MacRae, Gary Yang, Hak Choy, Gary Y. Yang

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Original language	American English
Title of host publication	Chemoradiation in Cancer Therapy
DOIs	https://doi.org/10.1007/978-1-59259-325-5_6
State	Published - Jan 1 2003

Disciplines

Oncology
Medicine and Health Sciences

Access to Document

10.1007/978-1-59259-325-5_6License: Unspecified

OpenUrl availability

Full text

Cite this

@inbook{f2ba160dbb31488e8a23d23bb6a1dc9f,

title = "The Role of Gemcitabine in Combined Modality Therapy",

author = "Jerome Landry and William Blackstock and MacRae, {Robert M.} and Gary Yang and Hak Choy and Yang, {Gary Y.}",

note = "Part of the Cancer Drug Discovery and Development book series (CDDD) Gemcitabine is a novel pyrimidine nucleoside analog with a broad spectrum of clinical antitumor activity. In addition to its initial approved indication in pancreatic carcinoma, gemcitabine has been licensed for the treatment of nonsmall-cell lung cancer (NSCLC) (1).",

year = "2003",

month = jan,

day = "1",

doi = "10.1007/978-1-59259-325-5_6",

language = "American English",

booktitle = "Chemoradiation in Cancer Therapy",

}

TY - CHAP

T1 - The Role of Gemcitabine in Combined Modality Therapy

AU - Landry, Jerome

AU - Blackstock, William

AU - MacRae, Robert M.

AU - Yang, Gary

AU - Choy, Hak

AU - Yang, Gary Y.

N1 - Part of the Cancer Drug Discovery and Development book series (CDDD) Gemcitabine is a novel pyrimidine nucleoside analog with a broad spectrum of clinical antitumor activity. In addition to its initial approved indication in pancreatic carcinoma, gemcitabine has been licensed for the treatment of nonsmall-cell lung cancer (NSCLC) (1).

PY - 2003/1/1

Y1 - 2003/1/1

UR - https://link.springer.com/content/pdf/10.1007%2F978-1-59259-325-5_6.pdf

U2 - 10.1007/978-1-59259-325-5_6

DO - 10.1007/978-1-59259-325-5_6

M3 - Chapter

BT - Chemoradiation in Cancer Therapy

ER -

The Role of Gemcitabine in Combined Modality Therapy

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this